These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33721267)

  • 1. Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis.
    Li Y; Mao X; Tang X; Mao H
    Rheumatol Ther; 2021 Jun; 8(2):711-727. PubMed ID: 33721267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
    Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
    J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis.
    Maccora I; Fusco E; Marrani E; Ramanan AV; Simonini G
    Rheumatology (Oxford); 2021 Feb; 60(2):568-587. PubMed ID: 33219694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.
    Simonini G; Druce K; Cimaz R; Macfarlane GJ; Jones GT
    Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1073-84. PubMed ID: 24740981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
    Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
    J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.
    Lanz S; Seidel G; Skrabl-Baumgartner A
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):132. PubMed ID: 34419092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
    PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety.
    Adler BL; Wang CJ; Bui TL; Schilperoort HM; Armstrong AW
    Semin Arthritis Rheum; 2019 Jun; 48(6):1093-1104. PubMed ID: 30446173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis.
    Yang HH; Huang Y; Zhou XC; Wang RN
    World J Clin Cases; 2022 Jun; 10(18):6091-6104. PubMed ID: 35949827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis.
    Cai W; Gu Y; Cui H; Cao Y; Wang X; Yao Y; Wang M
    Front Pharmacol; 2018; 9():138. PubMed ID: 29618976
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
    Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
    Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.
    Bhoi P; Bessette L; Bell MJ; Tkaczyk C; Nantel F; Maslova K
    BMJ Open; 2017 Sep; 7(9):e015872. PubMed ID: 28928177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.